CN114164167B - 用于单细胞分选与增强ipsc重新编程的细胞培养平台 - Google Patents

用于单细胞分选与增强ipsc重新编程的细胞培养平台 Download PDF

Info

Publication number
CN114164167B
CN114164167B CN202111314859.6A CN202111314859A CN114164167B CN 114164167 B CN114164167 B CN 114164167B CN 202111314859 A CN202111314859 A CN 202111314859A CN 114164167 B CN114164167 B CN 114164167B
Authority
CN
China
Prior art keywords
cells
cell
inhibitor
pluripotent
pluripotency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111314859.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114164167A (zh
Inventor
巴莱姆·瓦拉莫河
拉姆泽伊·阿布加罗尔
彼得·弗林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fate Therapeutics Inc
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of CN114164167A publication Critical patent/CN114164167A/zh
Application granted granted Critical
Publication of CN114164167B publication Critical patent/CN114164167B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/148—Transforming growth factor alpha [TGF-a]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN202111314859.6A 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台 Active CN114164167B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201061426369P 2010-12-22 2010-12-22
US61/426,369 2010-12-22
US201161496991P 2011-06-14 2011-06-14
US61/496,991 2011-06-14
PCT/US2011/065900 WO2012087965A2 (en) 2010-12-22 2011-12-19 Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
CN201180068009.0A CN103380212B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180068009.0A Division CN103380212B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台

Publications (2)

Publication Number Publication Date
CN114164167A CN114164167A (zh) 2022-03-11
CN114164167B true CN114164167B (zh) 2025-02-21

Family

ID=46314809

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201180068009.0A Active CN103380212B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台
CN202111314859.6A Active CN114164167B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台
CN201710089787.7A Active CN106893692B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201180068009.0A Active CN103380212B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710089787.7A Active CN106893692B (zh) 2010-12-22 2011-12-19 用于单细胞分选与增强ipsc重新编程的细胞培养平台

Country Status (8)

Country Link
US (3) US9732319B2 (enExample)
EP (1) EP2655601A4 (enExample)
JP (6) JP6182456B2 (enExample)
KR (6) KR102703637B1 (enExample)
CN (3) CN103380212B (enExample)
AU (1) AU2011349446C1 (enExample)
CA (1) CA2822638C (enExample)
WO (1) WO2012087965A2 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061808B1 (en) 2009-02-03 2020-08-12 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
KR102703637B1 (ko) 2010-12-22 2024-09-05 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
CA2857295C (en) 2011-12-01 2021-06-29 New York Stem Cell Foundation Automated system for producing induced pluripotent stem cells or differentiated cells
US10428309B2 (en) * 2011-12-01 2019-10-01 New York Stem Cell Foundation, Inc. Systems and methods for producing stem cells and differentiated cells
JP6433902B2 (ja) * 2013-01-04 2018-12-05 国立大学法人京都大学 初期化幹細胞
EP2949746A4 (en) * 2013-01-23 2016-07-27 Tokyo Electron Ltd METHOD OF SUB-CULTURE OF PLURIPOTENT STEM CELLS
US10465165B2 (en) 2013-01-28 2019-11-05 Rutgers, The State University Of New Jersey Growth matrices for stem cell propagation in vitro and in tissue regeneration
SG10201803131TA (en) * 2013-02-18 2018-06-28 Univ Health Network Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells
WO2014200114A1 (en) * 2013-06-11 2014-12-18 Kyoto University Method of efficiently establishing induced pluripotent stem cells
WO2014201133A1 (en) * 2013-06-11 2014-12-18 President And Fellows Of Harvard College Compositions and methods for improving induced neuron generation
CN103333920A (zh) * 2013-06-18 2013-10-02 西北农林科技大学 一种建立猪iPS细胞系的培养基及其培养方法
CN104278008B (zh) * 2013-07-12 2020-08-21 北京宏冠再生医学科技有限公司 一种通过小分子化合物处理来制备多潜能干细胞的方法、试剂盒和用途
CN105392881B (zh) * 2013-07-23 2020-09-01 豪夫迈·罗氏有限公司 体细胞基于小分子转化为神经嵴细胞
KR101655383B1 (ko) * 2013-07-27 2016-09-08 고려대학교 산학협력단 소분자 화합물을 포함하는 만능성 줄기세포의 염색체 안정성 유지용 조성물
US10067145B2 (en) * 2013-10-30 2018-09-04 Toagosei Co., Ltd. Method for removing genomically unstable IPS cells and synthetic peptide used therefor
KR101697110B1 (ko) * 2013-11-01 2017-01-18 건국대학교 글로컬산학협력단 세포융합을 통한 줄기세포의 역분화능 측정 방법
CN103667349B (zh) * 2013-11-15 2017-02-15 安徽农业大学 一种高效获取猪诱导性多能干细胞的方法
KR102340553B1 (ko) * 2014-03-04 2021-12-21 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
AU2015261380B2 (en) 2014-05-16 2021-04-15 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN107075472A (zh) * 2014-08-22 2017-08-18 剑桥企业有限公司 重置多能干细胞
CN105441384B (zh) * 2014-09-26 2021-01-05 北京大学 一种制备动物和人类原始多潜能干细胞的方法，试剂盒及用途
EP3204021A4 (en) * 2014-10-07 2018-03-07 Nutech Medical, Inc. Mesenchymal stem cell diagnostic testing
GB201421092D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201421094D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
CN107614678B (zh) * 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
CN114058582A (zh) 2015-01-26 2022-02-18 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
US10738280B2 (en) 2015-03-18 2020-08-11 Ono Pharmaceutical Co., Ltd. Method for producing naïve pluripotent stem cells
CN104707173B (zh) * 2015-04-01 2017-03-29 中国人民解放军总医院 一种三维细胞培养平台、其制备方法及其使用方法
EP4070887A1 (en) * 2015-04-21 2022-10-12 Isolation Bio Inc. Methods for high throughput microbiology applications
US10712356B2 (en) 2015-04-21 2020-07-14 General Automation Lab Technologies Inc. Apparatus and method for picking biological sample
CN105624104B (zh) * 2015-06-01 2018-10-12 中国医学科学院血液病医院（血液学研究所） 一种提高人间充质干细胞功能的细胞处理方法
WO2017027280A1 (en) 2015-08-07 2017-02-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Chemical reprogramming to generate neuronal cells
WO2017040548A1 (en) * 2015-08-31 2017-03-09 I Peace, Inc. Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells
AU2016318774B2 (en) 2015-09-08 2022-08-18 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
JP6983762B2 (ja) 2015-09-08 2021-12-17 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 臨床グレードの網膜色素上皮細胞の再現性のある分化のための方法
ES2971677T3 (es) * 2015-09-08 2024-06-06 Sumitomo Pharma Co Ltd Método para la producción de tejido retiniano
IL257794B (en) * 2015-09-08 2022-09-01 Sumitomo Pharma Co Ltd A method for producing retinal pigment epithelial cells
AU2016338680B2 (en) 2015-10-16 2022-11-17 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
US10947502B2 (en) 2015-10-20 2021-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
ES2953925T3 (es) * 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes
CN115927199A (zh) 2015-11-04 2023-04-07 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
WO2017091943A1 (en) * 2015-11-30 2017-06-08 Hong Guan Ltd. Improved methods for reprograming non-pluripotent cells into pluripotent stem cells
RU2018128598A (ru) * 2016-01-08 2020-02-11 Кинити Ко., Лтд. Способ продуцирования стволовых клеток/клеток-предшественников печени из зрелых клеток печени с использованием низкомолекулярного соединения
WO2017134628A1 (en) * 2016-02-03 2017-08-10 The Regents Of The University Of California Methods and compositions for culturing stem cells
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
CN105950548A (zh) * 2016-05-26 2016-09-21 南京医科大学附属南京儿童医院 一种从间充质干细胞高效获取可跳动有功能心肌细胞的方法
SG11201900231RA (en) * 2016-07-19 2019-02-27 Accellta Ltd Culture media for culturing pluripotent stem cells in suspension
US20190194621A1 (en) * 2016-09-08 2019-06-27 Kyowa Hakko Bio Co., Ltd. Medium for culturing stem cells, method for culturing stem cells, growth promoter for stem cells, and cell composition and method for producing same
JP7134416B2 (ja) * 2016-10-28 2022-09-12 国立研究開発法人国立がん研究センター ヒト肝前駆細胞の調製方法
CN106754729B (zh) * 2016-12-31 2020-03-17 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法
CN110573610B (zh) 2017-03-08 2025-01-28 住友制药株式会社 视网膜色素上皮细胞的制备方法
IL269716B2 (en) 2017-04-18 2025-07-01 Fujifilm Cellular Dynamics Inc Antigen-specific immune effector cells
US20200147146A1 (en) * 2017-05-02 2020-05-14 Koji Tanabe Pharmaceutical composition and cosmetic composition
EP3406712A1 (en) 2017-05-26 2018-11-28 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Method for expanding stemness and differentiation potential of pluripotent cells
CN111278967A (zh) 2017-10-11 2020-06-12 菲特治疗公司 使用时序性和瞬时质粒载体表达系统进行细胞重编程
JP6680742B2 (ja) 2017-10-31 2020-04-15 大研医器株式会社 磁性粒子収集方法及び試験セット
US20190167724A1 (en) * 2017-12-04 2019-06-06 Caire Medical-Biotechnology International Co. Neuroprotective composition, preparation process thereof and medical uses thereof
CN108265025A (zh) * 2017-12-28 2018-07-10 安徽中盛溯源生物科技有限公司 一种人类诱导多能干细胞的重编程培养基
JPWO2019151386A1 (ja) * 2018-01-31 2021-01-07 富士フイルム株式会社 細胞の製造方法
JP7097050B2 (ja) * 2018-03-19 2022-07-07 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
CN119410584A (zh) * 2018-06-20 2025-02-11 拜奥拉米那公司 用于产生视网膜色素上皮细胞的方法和组合物
JPWO2020027094A1 (ja) * 2018-07-31 2021-09-16 サイアス株式会社 ｉＰＳ細胞を介して再生Ｔ細胞集団を製造する方法
JP2022501017A (ja) 2018-09-07 2022-01-06 チャ バイオテック カンパニー リミテッド 多能性幹細胞由来の間葉系幹細胞直接分化用培地、それを利用して間葉系幹細胞を製造する方法、及びそれによって製造された間葉系幹細胞
WO2020080550A1 (ja) * 2018-10-15 2020-04-23 Cynity株式会社 低分子化合物による内胚葉組織又は器官由来細胞からの幹／前駆細胞の作製方法
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
JP7692610B2 (ja) * 2019-02-26 2025-06-16 国立大学法人東北大学 ｉＰＳ細胞を用いた骨芽細胞塊の作製法
CN109938987B (zh) * 2019-03-15 2024-06-04 首都医科大学宣武医院 放置于口腔内部的抽动障碍治疗器
WO2020191350A1 (en) * 2019-03-20 2020-09-24 Ion Diagnostics Llc Methods and systems for assessing bioelectric patterns
KR20220016846A (ko) 2019-05-14 2022-02-10 알레프 팜스 리미티드 만능세포 응집체 및 그의 용도
CN112301052A (zh) 2019-08-01 2021-02-02 浙江霍德生物工程有限公司 一种通过体细胞重编程制备诱导多功能干细胞的方法
CN115103903A (zh) * 2019-09-19 2022-09-23 西北大学 用于人诱导型多能干细胞的具成本效益的培养基和操作方案
AU2021296296A1 (en) * 2020-06-22 2023-01-19 Life Technologies Corporation Methods and compositions for cultivating pluripotent cell suspensions
US20240034999A1 (en) * 2020-10-02 2024-02-01 Fate Therapeutics, Inc. Improved reprogramming, maintenance and preservation for induced pluripotent stem cells
GB202115676D0 (en) * 2021-11-01 2021-12-15 Icahn School Med Mount Sinai Methods and compositions for bat ipsc preparation and use
EP4170018A1 (en) * 2021-10-20 2023-04-26 Roslin Technologies Limited Ipsc induction and progeny derivation
WO2023067090A1 (en) * 2021-10-20 2023-04-27 Roslin Technologies Limited Ipsc induction and progeny derivation
CN114591894B (zh) * 2022-02-28 2024-01-09 中国人民解放军总医院 一种皮肤多能前体干细胞的制备方法及其应用
US20250051724A1 (en) * 2022-03-14 2025-02-13 Space F Corporation Medium composition for culturing porcine pluripotent stem cells
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2025152036A1 (en) * 2024-01-16 2025-07-24 Chiou Guang Yuh System and method for increasing the transduction capability and reprogramming efficiency in targeting cells and tissues
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102597221A (zh) * 2009-11-04 2012-07-18 细胞动力国际有限公司 使用化学品的游离重编程

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
KR940702451A (ko) 1991-09-06 1994-08-20 고야 다다시 4-아미로(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP0710283A4 (en) 1993-07-22 1997-07-02 Merck & Co Inc THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
AU6113396A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
BR9711154A (pt) 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
WO1998050048A1 (en) 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
JP3626206B2 (ja) 1997-06-13 2005-03-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｓｍａｄ６及びその使用
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20060263382A1 (en) 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
EP1100872A1 (en) 1998-07-24 2001-05-23 Carnegie Institution Of Washington Method for maintenance and propagation of germline stem cells using members of the tgf-beta family of growth factors
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
ATE292462T1 (de) 1999-01-07 2005-04-15 Warner Lambert Co Behandlung von asthma anhand von mek-inhibitoren
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
AU5250400A (en) 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
AU6865100A (en) 1999-09-02 2001-04-10 Mitsubishi Pharma Corporation Osteogenesis promoting agents
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
PE20021011A1 (es) 2001-03-23 2003-02-01 Bayer Corp Derivados quinazolinicos como inhibidores de la rho-quinasa
DE60218138T2 (de) 2001-03-23 2007-09-20 Bayer Pharmaceuticals Corp., West Haven Rho-kinase inhibitoren
EP1385946B1 (en) 2001-05-01 2009-12-23 National Research Council Of Canada A system for inducible expression in eukaryotic cells
WO2003027277A1 (en) 2001-09-21 2003-04-03 Japan Science And Technology Corporation Method of screening reporgramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs
ES2388968T3 (es) 2001-11-02 2012-10-22 Giuliani International Limited Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
ES2305435T3 (es) 2002-01-10 2008-11-01 Bayer Healthcare Ag Inhibidores de la rho-quinasa.
JP4469179B2 (ja) 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
JP4423043B2 (ja) 2002-01-23 2010-03-03 バイエル ファーマセチカル コーポレーション Ｒｈｏ−キナーゼ阻害剤
US20030204862A1 (en) 2002-03-05 2003-10-30 Ralf Kuehn Inbred embryonic stem-cell derived mice
TWI338685B (en) 2002-03-13 2011-03-11 Array Biopharma Inc N3 alkylated benzimid azole derivatives as mek inhibitors
US20050182040A1 (en) 2002-04-03 2005-08-18 Naonori Imazaki Benzamide derivatives
GB0210539D0 (en) 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
CA2506085A1 (en) 2002-11-15 2004-06-03 Ronald Lynn Merriman Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
ES2705683T3 (es) * 2002-12-16 2019-03-26 Technion Res & Dev Foundation Medio de cultivo de células madre pluripotentes
JP2006517234A (ja) 2003-02-10 2006-07-20 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
AU2003901099A0 (en) 2003-03-11 2003-03-27 Es Cell International Pte Ltd. Methods of inducing differentiation of stem cells
US20050075276A1 (en) 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses
US20070010008A1 (en) 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
EP1732581A4 (en) 2003-06-20 2008-06-04 Univ California San Diego POLYPEPTIDE TRANSDUCTION AND FUSOGENIC PEPTIDES
RU2392315C2 (ru) 2003-10-03 2010-06-20 Кейити ФУКУДА Способ индукции дифференциации стволовых клеток в миокардиальные
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
JP2007508026A (ja) 2003-10-16 2007-04-05 ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラ Ｅｓ細胞の自己再生および系統仕様の制御ならびにそのための培地
WO2005049812A1 (en) 2003-11-19 2005-06-02 Australian Stem Cell Centre Limited Methods for producing blood products from pluripotent cells in cell culture
AU2004293436B2 (en) 2003-11-19 2010-12-09 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
JP2007519754A (ja) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
WO2005108416A2 (en) 2004-04-21 2005-11-17 The University Of Chicago Myosin light chain kinase inhibitors and their use
WO2006020919A2 (en) 2004-08-13 2006-02-23 University Of Georgia Research Foundation, Inc. Compositions and methods for self-renewal and differentiation in human embryonic stem cells
US20080268533A1 (en) 2004-08-25 2008-10-30 University Of Georgia Research Foundation, Inc. Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells
WO2006088867A2 (en) 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
KR20080019236A (ko) 2005-05-18 2008-03-03 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
CA2617611A1 (en) 2005-08-01 2007-02-08 Nupotential, Llc Production of reprogrammed cells with restored potential
US20080242594A1 (en) 2005-09-08 2008-10-02 Mckay Ronald D G Methods for Promoting Stem Cell Proliferation and Survival
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
GB0601538D0 (en) 2006-01-26 2006-03-08 Univ Birmingham Epigenetic analysis
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo COMMON USE OF A TGF BETA SIGNAL HEMMER AND AN ANTITUMORAL AGENT
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
AU2007232393A1 (en) 2006-03-30 2007-10-11 The University Court Of The University Of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
GB0615327D0 (en) * 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
GB2452186B (en) 2006-05-02 2011-01-26 Wisconsin Alumni Res Found Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
US20070298496A1 (en) * 2006-06-23 2007-12-27 Hung-Chih Kuo Method of deriving pluripotent stem cells from a single blastomere
US7884107B2 (en) 2006-06-30 2011-02-08 Merck Substituted piperidines that increase P53 activity and the uses thereof
CA2657227A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
US20080020014A1 (en) 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
JP2008099662A (ja) 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
ZA200901914B (en) * 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
GB0622395D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Methods relating to pluripotent cells
WO2008089351A1 (en) 2007-01-17 2008-07-24 Wisconsin Alumni Research Foundation Improved culture of stem cells
US20100172883A1 (en) 2007-01-19 2010-07-08 Bruneau Benoit Gaetan Methods of generating cardiomyocytes
CN101641436A (zh) 2007-01-30 2010-02-03 佐治亚大学研究基金会 用于产生内胚层和中胚层细胞系及多能游走细胞（mmc）的早期中胚层细胞即稳定的中内胚层细胞群
WO2008105630A1 (en) 2007-02-27 2008-09-04 Procell Therapeutics Inc. Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells
EP3449923A1 (en) 2007-03-07 2019-03-06 MEI Pharma, Inc. Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
EP3640326A1 (en) 2007-04-18 2020-04-22 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
US7878210B2 (en) 2007-06-04 2011-02-01 Philip Morris Usa Inc. Cellulose acetate fiber modification
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
AU2008272949B2 (en) 2007-06-29 2014-05-15 FUJIFILM Cellular Dynamics, Inc. Automated method and apparatus for embryonic stem cell culture
WO2009032456A2 (en) 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
EP2198011B1 (en) 2007-08-31 2016-06-08 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
CA2660123C (en) 2007-10-31 2017-05-09 Kyoto University Nuclear reprogramming method
WO2009061442A1 (en) 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
JP4604076B2 (ja) 2007-11-07 2010-12-22 国立大学法人静岡大学 燃料電池用電解質膜
EP2227540A4 (en) 2007-11-29 2011-11-02 Children S Hospital Of Orange County DIFFERENTIATION OF HUMAN CELLS
US20110190729A1 (en) 2007-11-30 2011-08-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving sox2 protein
WO2009067757A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving oct4 protein
EP2268796A1 (en) 2008-03-17 2011-01-05 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
SG10202103401QA (en) 2008-03-17 2021-05-28 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
CN101550406B (zh) 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
CN101848994A (zh) 2008-07-30 2010-09-29 国立大学法人京都大学 有效建立诱导的多能干细胞的方法
EP2331696A1 (en) * 2008-08-12 2011-06-15 Cellular Dynamics International, Inc. Methods for the production of ips cells
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
CA2742583C (en) * 2008-11-04 2022-09-27 Viacyte, Inc. Stem cell aggregate suspension compositions and methods for differentiation thereof
CA2995883C (en) 2008-12-03 2023-01-24 The Scripps Research Institute Compounds and methods for stabilizing cell cultures
CA2688804A1 (en) 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic vector for human induced pluripotent stem cell production
WO2010077955A1 (en) 2008-12-17 2010-07-08 The Scripps Research Institute Generation and maintenance of stem cells
US20120122212A1 (en) 2009-03-06 2012-05-17 Marica Grskovic Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
EP2414510A4 (en) 2009-04-03 2013-04-17 Mclean Hospital Corp INDUCED PLURIPOTENTIAL STEM CELLS
JP2012523240A (ja) * 2009-04-13 2012-10-04 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 幹細胞培養のための方法および組成物
EP2435558A4 (en) * 2009-05-27 2013-05-22 Salk Inst For Biological Studi GENETICALLY CORRECTED NON-DISABLED INDUCED PLURIPOTENTER STEM CELLS
US8524498B2 (en) 2009-05-29 2013-09-03 The General Hospital Corporation Methods and compositions for homologous recombination in human cells
WO2010137348A1 (en) 2009-05-29 2010-12-02 Keio University Method for selecting clone of induced pluripotent stem cells
CA2770412C (en) 2009-08-07 2018-09-11 Kyoto University Method of efficiently establishing induced pluripotent stem cells
ES2938049T3 (es) 2009-10-16 2023-04-04 Scripps Research Inst Inducción de células pluripotentes
SG10201702120VA (en) * 2009-10-31 2017-05-30 Genesis Technologies Ltd Methods for Reprogramming Cells and Uses Thereof
DK2499236T3 (da) 2009-11-12 2020-03-23 Technion Res & Dev Foundation Dyrkningsmedier, cellekulturer og metoder til dyrkning af pluripotente stamceller i en udifferentieret tilstand
JP5827220B2 (ja) 2010-01-22 2015-12-02 国立大学法人京都大学 人工多能性幹細胞の樹立効率改善方法
CA2789774C (en) 2010-02-17 2024-01-23 Biotime Inc. Methods for telomere length and genomic dna quality control analysis in pluripotent stem cells
WO2011109695A1 (en) 2010-03-05 2011-09-09 Texas Heart Institute Ets2 and mesp1 generate cardiac progenitors from fibroblasts
AU2011235212B2 (en) 2010-03-31 2014-07-31 The Scripps Research Institute Reprogramming cells
JPWO2011158852A1 (ja) 2010-06-15 2013-08-19 国立大学法人 東京大学 誘導型多能性幹細胞の製造方法
US20110306516A1 (en) 2010-06-15 2011-12-15 The New York Stem Cell Foundation Methods for producing induced pluripotent stem cells
AU2011267849B2 (en) * 2010-06-15 2015-02-05 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
EP2601289B1 (en) * 2010-08-04 2017-07-12 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
KR102703637B1 (ko) 2010-12-22 2024-09-05 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
WO2013070852A2 (en) 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
EP2788476B1 (en) 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013159103A1 (en) 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
WO2013176197A1 (ja) 2012-05-22 2013-11-28 国立大学法人 東京大学 抗原特異的ｔ細胞の製造方法
US9166832B1 (en) 2013-10-04 2015-10-20 Altera Corporation Methods and apparatus for decision feedback equalization adaptation
KR102340553B1 (ko) 2014-03-04 2021-12-21 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
AU2016338680B2 (en) 2015-10-16 2022-11-17 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
ES2953925T3 (es) 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102597221A (zh) * 2009-11-04 2012-07-18 细胞动力国际有限公司 使用化学品的游离重编程

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A chemical platform for improved induction of human iPS cells;Lin等;《Nature methods》;第6卷(第11期);第805-808页 *
Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs;Jacob Hanna等;《PNAS》;20100504;第107卷(第20期);第9222-9227页 *
Lin等.A chemical platform for improved induction of human iPS cells.《Nature methods》.2009,第6卷(第11期),第805-808页. *
Reprogramming of human primary somatic cells by OCT4 and chemical compounds;Saiyong Zhu 等;《Cell Stem Cell》;第7卷(第6期);第651-655页 *
Saiyong Zhu 等.Reprogramming of human primary somatic cells by OCT4 and chemical compounds.《Cell Stem Cell》.2010,第7卷(第6期),第651-655页. *

Also Published As

Publication number Publication date
KR102160721B1 (ko) 2020-09-29
US20170362569A1 (en) 2017-12-21
AU2011349446A1 (en) 2013-04-11
KR102482184B1 (ko) 2022-12-28
CA2822638A1 (en) 2012-06-28
JP2022097516A (ja) 2022-06-30
KR20140063501A (ko) 2014-05-27
KR20200113286A (ko) 2020-10-06
JP7606569B2 (ja) 2024-12-25
JP2020108399A (ja) 2020-07-16
AU2011349446B2 (en) 2015-09-03
US10844356B2 (en) 2020-11-24
US20140220681A1 (en) 2014-08-07
JP7513412B2 (ja) 2024-07-09
KR20210097834A (ko) 2021-08-09
CN106893692A (zh) 2017-06-27
US12415989B2 (en) 2025-09-16
CN103380212A (zh) 2013-10-30
JP2025039573A (ja) 2025-03-21
KR102703637B1 (ko) 2024-09-05
CN114164167A (zh) 2022-03-11
US9732319B2 (en) 2017-08-15
EP2655601A2 (en) 2013-10-30
KR20190049918A (ko) 2019-05-09
AU2011349446C1 (en) 2016-01-21
WO2012087965A2 (en) 2012-06-28
KR20230006038A (ko) 2023-01-10
JP2014501108A (ja) 2014-01-20
JP2017158585A (ja) 2017-09-14
EP2655601A4 (en) 2014-09-10
JP7350127B2 (ja) 2023-09-25
KR20170064555A (ko) 2017-06-09
US20210079359A1 (en) 2021-03-18
JP6682474B2 (ja) 2020-04-15
JP6182456B2 (ja) 2017-08-23
JP2023138509A (ja) 2023-10-02
CN106893692B (zh) 2021-11-26
WO2012087965A3 (en) 2012-10-04
KR101975688B1 (ko) 2019-05-07
CN103380212B (zh) 2017-04-05
CA2822638C (en) 2021-02-16

Similar Documents

Publication Publication Date Title
JP7606569B2 (ja) 単細胞選別のための細胞培養プラットホームおよびｉＰＳＣの再プログラミングの増強
KR102340553B1 (ko) 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
CN117737124A (zh) 用于诱导和维护基态多能性的平台
HK40068498A (zh) 用於单细胞分选与增强ipsc重新编程的细胞培养平台
HK1239743A1 (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
HK1191049A (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
HK1191049B (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
HK1239743B (zh) 用於单细胞分选与增强ipsc重新编程的细胞培养平台

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068498

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant